Eledon Stock Analysis

ELDN -  USA Stock  

USD 4.09  0.34  7.67%

The latest slide in stock price could raise concerns from institutional investors as the firm it trading at a share price of 4.09 on very low momentum in volume. The company executives have failed to build on market volatilities in December. However, diversifying your overall positions with Eledon Pharmaceuticals may protect your principal portfolio during upcoming market swings. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.69. This high volatility is attributed to the latest market swings and not so good earnings reports for some of the Eledon Pharmaceuticals partners.
Continue to Investing Opportunities.

Eledon Stock Analysis 

 
Refresh
The Eledon Pharmaceuticals stock analysis report makes it easy to digest most publicly released information about Eledon Pharmaceuticals and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Eledon Stock analysis module also helps to analyze the Eledon Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.

Eledon Stock Analysis Notes

About 61.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.37. Some equities with similar Price to Book (P/B) outperform the market in the long run. Eledon Pharmaceuticals has Price/Earnings To Growth (PEG) ratio of 0.03. The entity recorded a loss per share of 2.68. The firm had not issued any dividends in recent years. Eledon Pharmaceuticals had a split on the 5th of October 2020. Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis , and requiring an organ or cell-based transplant. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California. Eledon Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people. To learn more about Eledon Pharmaceuticals call the company at 949 238 8090 or check out https://eledon.com.

Eledon Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Eledon Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Eledon Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Eledon Pharmaceuticals generated a negative expected return over the last 90 days
Eledon Pharmaceuticals has high historical volatility and very poor performance
Eledon Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (31.6 M).
Eledon Pharmaceuticals currently holds about 94.04 M in cash with (29.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.57, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Eledon Pharmaceuticals has a frail financial position based on the latest SEC disclosures
Roughly 61.0% of the company shares are held by institutions such as insurance companies

Eledon Pharmaceuticals Upcoming and Recent Events

Earnings reports are used by Eledon Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Eledon Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report29th of March 2022
Next Earnings Report12th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End29th of March 2022
Last Quarter Report30th of September 2021
Last Earning Announcement31st of December 2020

Eledon Largest EPS Surprises

Earnings surprises can significantly impact Eledon Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2015-03-12
2014-12-31-0.34-0.280.0617 
2015-05-12
2015-03-31-0.31-0.59-0.2890 
2016-08-04
2016-06-30-4.82-5.4-0.5812 
View All Earnings Estimates

Eledon Pharmaceuticals SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Eledon Pharmaceuticals prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Eledon Pharmaceuticals investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Eledon Pharmaceuticals specific information freely available to individual and institutional investors to make a timely investment decision.
13th of January 2022
Financial Statements and Exhibits. Unregistered Sales of Equity Securities
View
10th of January 2022
Unclassified Corporate Event
View
12th of November 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
9th of September 2021
Unclassified Corporate Event
View
12th of August 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
2nd of August 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
2nd of July 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
16th of June 2021
Submission of Matters to a Vote of Security Holders
View

Eledon Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Eledon Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Eledon Pharmaceuticals backward and forwards among themselves. Eledon Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Eledon Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Spire Wealth ManagementCommon Shares850K
Bvf IncCommon Shares1.4 M8.4 M
Logos Global Management LpCommon Shares1.3 M8.3 M
Cormorant Asset Management LpCommon Shares1.3 M8.1 M
Fmr LlcCommon SharesM6.2 M
Woodline Partners LpCommon Shares781.4 K4.8 M
Vanguard Group IncCommon Shares670.5 K4.1 M
Note, although Eledon Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Eledon Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 63.38 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Eledon Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Eledon Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Eledon Profitablity

Eledon Pharmaceuticals' profitability indicators refer to fundamental financial ratios that showcase Eledon Pharmaceuticals' ability to generate income relative to its revenue or operating costs. If, let's say, Eledon Pharmaceuticals is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Eledon Pharmaceuticals' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Eledon Pharmaceuticals' profitability requires more research than a typical breakdown of Eledon Pharmaceuticals' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Average Assets(0.20) (0.22) 
Return on Average Equity(0.35) (0.38) 
Return on Invested Capital(1.37) (1.48) 

Management Efficiency

The entity has return on total asset (ROA) of (11.2) % which means that it has lost $11.2 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (17.69) %, meaning that it created substantial loss on money invested by shareholders. Eledon Pharmaceuticals management efficiency ratios could be used to measure how well eledon pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return on Average Assets is estimated to slide to -0.22. The value of Return on Average Equity is estimated to slide to -0.38. Eledon Pharmaceuticals Average Assets are quite stable at the moment as compared to the past year. The company's current value of Average Assets is estimated at 128.42 Million. Tangible Asset Value is expected to rise to about 184.3 M this year, although the value of Return on Average Assets will most likely fall to (0.22) .
Last ReportedProjected for 2022
Book Value per Share 151.01  162.93 
Enterprise Value over EBIT 4.60  4.96 
Enterprise Value over EBITDA 4.60  4.96 
Price to Book Value 0.10  0.11 
Tangible Assets Book Value per Share 92.10  94.53 
Enterprise Value-83 M-85.2 M
Tangible Asset Value170.8 M184.3 M

Technical Drivers

As of the 19th of January, Eledon Pharmaceuticals shows the coefficient of variation of (1,116), and Mean Deviation of 3.34. Eledon Pharmaceuticals technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down nineteen technical drivers for Eledon Pharmaceuticals, which can be compared to its rivals. Please confirm Eledon Pharmaceuticals treynor ratio, and the relationship between the standard deviation and downside variance to decide if Eledon Pharmaceuticals is priced favorably, providing market reflects its regular price of 4.09 per share. Given that Eledon Pharmaceuticals has jensen alpha of (0.43), we urge you to verify Eledon Pharmaceuticals's prevailing market performance to make sure the company can sustain itself at a future point.

Eledon Pharmaceuticals Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Eledon Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Eledon Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target. View also all equity analysis or get more info about bollinger bands overlap studies indicator.

Eledon Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Eledon Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Eledon Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Eledon Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Eledon Pharmaceuticals Technical and Predictive Indicators

Eledon Pharmaceuticals Forecast Models

Eledon Pharmaceuticals time-series forecasting models is one of many Eledon Pharmaceuticals' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Eledon Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Eledon Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Eledon Pharmaceuticals stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Eledon shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Eledon Pharmaceuticals. By using and applying Eledon Stock analysis, traders can create a robust methodology for identifying Eledon entry and exit points for their positions.
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis , and requiring an organ or cell-based transplant. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California. Eledon Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people.

Current Eledon Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Eledon analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Eledon analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
28.8Strong Buy5Odds
Eledon Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Eledon analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Eledon stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Eledon Pharmaceuticals, talking to its executives and customers, or listening to Eledon conference calls.
Eledon Analyst Advice Details

Eledon Stock Analysis Indicators

Eledon Pharmaceuticals stock analysis indicators help investors evaluate how Eledon Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Eledon Pharmaceuticals shares will generate the highest return on investment. By understating and applying Eledon Pharmaceuticals stock analysis, traders can identify Eledon Pharmaceuticals position entry and exit signals to maximize returns.
Quick Ratio23.24
Fifty Two Week Low3.8100
Shares Short Prior Month179.52k
Average Daily Volume Last 10 Day114.62k
Average Daily Volume In Three Month87.1k
Shares Percent Shares Out0.97%
Short Percent Of Float0.97%
Forward Price Earnings-1.76
Float Shares9.5M
Fifty Two Week High22.9100
Enterprise Value To Ebitda0.72
Fifty Day Average4.7519
Two Hundred Day Average6.9922
Continue to Investing Opportunities. Note that the Eledon Pharmaceuticals information on this page should be used as a complementary analysis to other Eledon Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.

Complementary Tools for Eledon Stock analysis

When running Eledon Pharmaceuticals price analysis, check to measure Eledon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eledon Pharmaceuticals is operating at the current time. Most of Eledon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eledon Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Eledon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eledon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Is Eledon Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eledon Pharmaceuticals. If investors know Eledon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eledon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Eledon Pharmaceuticals is measured differently than its book value, which is the value of Eledon that is recorded on the company's balance sheet. Investors also form their own opinion of Eledon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eledon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eledon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eledon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eledon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Eledon Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eledon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.